特发性血小板减少性紫癜患者GPIIb/IIIa、CD62P表达探讨

目的检测原发性血小板减少性紫癜 (ITP)患者血小板表面GPIIb/IIIa、CD62P的表达情况 ,以探讨其在ITP患者中的临床应用价值。方法采用美国BD公司的FACSCalibur流式细胞仪 ,对32例ITP患者、17例非免疫性血小板减少、21例其它自身免疫性疾病及20例健康正常人的血小板表面GPIIb/IIIa、CD62P的表达情况进行了分析测定。结果ITP患者GPIIb/IIIa血小板阳性表达率明显高于其它三组 (P<0.01) ,但CD62P血小板阳性表达率四组无明显差别(P>0.05) ,15例无临床症状ITP患者GPIIb/IIIa表达明显高于17例有临床症状ITP患者的表达(P<0.01)。结论GPIIb/IIIa作为监测血小板活化指标 ,对ITP的鉴别诊断及监测病情发展、判断预后具有重要意义 ;ITP患者的GPIIb/IIIa表达明显增高 ,但CD62P表达并不增高 ,CD62P并非监测ITP患者循环中活化血小板的理想标志物     

冠心病患者血小板膜糖蛋白CD63;CD62P和TSD的表达

目的研究冠心病患者血小板膜糖蛋白的表达。方法采用流式细胞术(FCM) ,对113例冠心病患者及37例健康人血小板膜糖蛋白(MGP)CD63 ,CD62P和凝血酶敏感蛋白(TSD)进行了检测。结果患者组CD63,CD62P和TDS3种MGP的阳性表达率分别为 :(5.3±4.0) % ,(5.8±3.3)%和(4.7±3.7)% ,均显著高于正常对照组 ,分别为 :(1.0±0.6) % ,(1.4±0.5)%和(1.6±0.6)%(P<0.01)。结论用FCM检测活化血小板 ,结果准确 ,特异性和灵敏度高 ,可反映单个或亚群血小板质膜上活化抗原的变化 ,对血栓性疾病的诊断及治疗具有重要的意义。     

CD123+CD11c-pDC在初发类风湿关节炎患者外周血及关节液中的表达

目的:探讨外周血及关节液中浆细胞样树突状细胞(Plasmaetoid dendritic cell,pDC)的数量在初发类风湿关节炎(RA)患者中的表达,进一步明确pDC在类风湿关节炎发病机制中的作用.方法:采集RA组患者(30人),骨关节炎(0A)组(25人),健康对照组(25人)抗凝外周血及关节液,流式细胞术检测CD123+ CD11c-pDC的表型及数量.结果:活动性RA患者外周血中CD123+ CD11c-pDC(1.69％±0.97％)与OA组(5.38％±2.31％)相比含量减少,差异具有统计学意义(P＜0.05),与健康对照组(5.63％±2.33％)相比含量减少,差异具有统计学意义(P＜0.05),后两者相比差异无统计学意义(P＞0.05).关节液中两组CD123+ CD1 1c-pDC含量差异无统计学意义(P＞0.05),pDC与DAS28评分及疾病的活动度指标RF、ESR、CRP无相关性.结论:初发RA患者体内外周血中CD123+ CD1 1c pDC含量减少与机体免疫功能紊乱有关,这对进一步阐明RA的发病机制及探索新的靶向治疗起到一定的积极作用.     

血小板生成素及血小板生成素Ⅱ对人血小板活化的影响

目的:检测血小板生成素(TPO)及TPOⅡ在体外对人血小板活化的影响。方法:取正常健康成人富血小板血浆,分别与血小板生成素(rhTPO)、TPOⅡ及磷酸盐溶液孵化,通过荧光单克隆抗体标记血小板表面CD62P及CD41分子,用流式细胞术测定CD62P/CD41比率,观察各组血小板活化率。结果:rhTPO、TPOⅡ组血小板活化率与PBS组无明显差异,P＞0.05。结论:血小板生成素不会导致血小板异常活化,可应用于血小板生成减少的各种情况。     

急性脑梗死患者外周血淋巴细胞的早期活化与其黏附分子表达的关系研究

目的：探讨脑梗死患者外周血T淋巴细胞早期活化与黏附分子CD54和血小板P选择素（CD62P）、溶酶体颗粒糖蛋白63（CD63）的动态变化及临床意义。方法：用流式细胞仪检测32例脑梗死患者发病3d、7d外周血T淋巴细胞CD69和CD54及血小板CD62P、CD63的表达水平,并与35例健康者进行比较。结果：急性脑梗死（MS）患者发病72h内、7d外周血CD3^＋CD69^＋与CD3^＋CD54^＋及血小板CD62P与CD63表达阳性率均显著高于对照组（P〈0．01）,7d时各值虽较72h略降低,但差别无统计学意义（P〉0．05）;急性脑梗死患者发病72h内CD3^＋CD69^＋与CD3^＋CD54^＋、CD62P和CD63的表达无明显相关性（r值分别为-0．218、-0．117、-0．224,P〉0．05）;而CD54与CD62P、CD63的表达呈明显正相关（r=0．468,P〈0．01;r=0．397,P〈0．05）。结论：急性脑梗死后T淋巴细胞活化程度增强,其细胞表面CD54分子表达增高,同时血小板表面CD62P和CD63分子表达增加,活化的T淋巴细胞和血小板介导了白细胞与血小板及内皮细胞的黏附,加速了脑梗死的发生和发展,进一步加重了脑组织的损伤。     

隐匿型肾小球肾炎外周血CD44、CD54、CD62P的表达及意义

目的:探讨隐匿型肾小球肾炎外周血粘附分子CD44、CD54、CD62P的表达与疾病的关系。方法:采用流式细胞全血免疫荧光直标术对25例隐匿型肾小球肾炎患者外周血进行CD44、CD54、CD62P标记后,上流式细胞仪检测。结果:隐匿型肾小球肾炎患者外周血CD44、CD54、CD62P的表达显著高于正常对照(P<0.01),而且肉眼血尿组CD44、CD54、CD62P的表达显著高于尿检异常组(P<0.01)。结论:黏附分子CD44、CD54、CD62P可能介导和参与了隐匿型肾小球肾炎的发生及发展过程,外周血粘附分子CD44、CD54、CD62P的检测可为临床隐匿型肾小球肾炎的诊断和治疗提供分子依据。     

GD患者外周血CD4+CD28-T细胞亚群的表型特征及临床意义

检测Graves病(GD)患者外周血CD4~+CD28-T细胞水平及其表面CD45RO/CD45RA及ICOS的表达,探讨CD4~+ CD28-T细胞亚群在GD免疫致病机制中的作用。采用三色荧光抗体染色及流式细胞术检测了42例初发GD患者和30例健康者外周血中CD4~+CD28-T细胞的百分率及其表面CD45RO/CD45RA和ICOS表达水平,同时检测其甲状腺功能并进行相关性分析。结果GD患者外周血中CD4~+CD28-T细胞百分率明显高于健康对照组,并高表达ICOS分子,与FT3水平显著正相关;与健康对照组相比,GD患者CD4~+CD28~-CD45RO~+T细胞百分率也显著增高,而CD4~+CD28~-CD45RA~+T细胞呈下降趋势,FT3、FT4水平与CD4~+CD28-T细胞表面CD45RO的表达率呈正相关,而FT3水平与CD45RA表达呈负相关。结论GD患者外周血CD4~+CD28~-T细胞异常增高,表面高表达ICOS分子,具有记忆性细胞的表型特征,与甲状腺功能异常有一定的相关性,CD4~+CD28-T细胞可能是参与GD免疫病理反应的自身反应性T细胞。     

特发性血小板减少性紫癜患者GPⅡb/Ⅲa、CD62P表达探讨

目的检测原发性血小板减少性紫癜(ITP)患者血小板表面GPⅡb/Ⅲa、CD62P的表达情况,以探讨其在ITP患者中的临床应用价值.方法采用美国BD公司的FACSCalibur流式细胞仪,对32例ITP患者、17例非免疫性血小板减少、21例其它自身免疫性疾病及20例健康正常人的血小板表面GPⅡb/Ⅲa、CD62P的表达情况进行了分析测定.结果ITP患者GPⅡb/Ⅲa血小板阳性表达率明显高于其它三组(P＜0.01),但CD62P血小板阳性表达率四组无明显差别(P＞0.05),15例无临床症状ITP患者GPⅡb/Ⅲa表达明显高于17例有临床症状ITP患者的表达(P＜0.01).结论GPⅡb/Ⅲa作为监测血小板活化指标,对ITP的鉴别诊断及监测病情发展、判断预后具有重要意义;ITP患者的GPⅡb/Ⅲa表达明显增高,但CD62P表达并不增高,CD62P并非监测ITP患者循环中活化血小板的理想标志物.     

慢性肺心病患者PAC-1、CD62p的变化及临床意义

目的：探讨慢性肺心病患者血小板膜糖蛋白PAC-1、CD62p的变化及其临床意义。方法：用三色全血流式细胞术测定加例慢性肺心病患者外周血中血小板PAC-1、CD62p的表达水平，并与30例健康对照者比较。用超声心动图检测慢性肺心病患者肺动脉收缩压。结果：慢性肺心病组PAC-1、CD62p的表达均明显高于正常对照组（均P〈0．001），并与肺动脉收缩压呈正相关。慢性肺心病患者PAC-1的变化与CD62p之间有显著的正相关（r=0．73；P〈0．001）。结论：慢性肺心病患者血小板明显活化，其活化程度与肺动脉高压关系密切。     

miR-146a调控血小板免疫活化功能

目的探讨miR-146a对血小板免疫活化功能的影响。方法流式细胞术检测冠心病(n=31)及健康成年人(n=35)全血中血小板PAC-1、CD62-P阳性率,q-PCR及光比浊法分别检测血浆中miR-146a及血小板聚集率;培养K562细胞,佛波酯(PMA)诱导分化为巨核细胞后,分别转染miR-146a mimics、inhibitor及其阴性对照,Western blot检测转染后细胞中TLR-4、PAC-1及CD62-P表达水平。结果冠心病患者miR-146a、血小板聚集率及PAC-1、CD62-P阳性率较对照组升高(P0.05);转染miR-146a mimics后,TLR-4、PAC-1和CD62-P表达水平升高(P0.05)。结论miR-146a可能依赖血小板TLR-4信号通路,介导血小板免疫活化进而促进血小板聚集,加速血栓形成。     

Older age of rheumatoid arthritis onset is associated with higher activation status of peripheral blood CD4(+) T cells and disease activity

Rheumatoid arthritis (RA) is a chronic inflammatory disease, with a clinical manifestation both systemic and in joints. It has been suggested that age at disease onset and/or patients' age have influence on disease activity and clinical outcome. The reasons for the different course of RA in older people are not known; however, the activation status of peripheral blood lymphocytes could be responsible. Our aim was to relate expression of activation markers in peripheral blood CD4(+) T cells of RA patients with patients' age and/or onset age and disease activity measured by DAS28. Seventy RA patients were included into the immunological study. Two separation criteria were performed: based on age of RA onset and on the biological age of patients. We examined different activation markers, CD69, CD25, CD95 and human leucocyte antigen D-related (HLA-DR), on the CD4(+) T cell surface. Division of RA patients in 10-year intervals at 40, 50 and 60 years revealed that RA patients with later disease onset were characterized by higher DAS28. This phenomenon was not limited to the division at 60 years of age but, surprisingly, the major differences were found for the 40-year onset division. Analysis of all four components of DAS28 revealed that disease activity in older disease onset was dependent on all components. Older-onset RA patients had a higher percentage of CD4(+) CD25(+) and CD4(+) CD95(+) T cells. Summarizing the major differences in DAS28 and activation status of CD4(+) T cells observed for onset of disease at 40 years seems to be the most informative about the immunological status of RA patients.     

The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke

Introduction

Low-density lipoprotein cholesterol (LDL-C) has been reported to increase platelet activation. Reducing the level of LDL-C with statins induces important pleiotropic effects such as platelet inhibition. This association between platelet activity and statin therapy may be clinically important in reducing the risk of ischemic stroke. We investigated the effect of simvastatin therapy on platelet activation markers (platelet CD62P, sP-selectin, and platelet-derived microparticles (PDMPs)) in hyperlipidemic patients after ischemic stroke.

Material and methods

The study group consisted of 21 hyperlipidemic patients after ischemic stroke confirmed by CT, and 20 healthy subjects served as controls. We assessed the CD62P expression on resting and thrombin-activated blood platelets. CD62P and PDMPs were analyzed by the use of monoclonal antibodies anti-CD61 and anti-CD62 on a flow cytometer. The level of sP-selectin in serum was measured by the ELISA (enzyme-linked immunosorbent assay) method. All markers were re-analyzed after 6 months of treatment with simvastatin (20 mg/day).

Results

Hyperlipidemic patients presented a significantly higher percentage of CD62+ platelets and higher reactivity to thrombin compared to control subjects. After simvastatin therapy hyperlipidemic patients showed a reduction of the percentage of resting CD62P(+) platelets (p = 0.005) and a reduction of expression and percentage of CD62P(+) platelets after activation by thrombin (median p < 0.05; percentage: p = 0.001). A decrease of sP-selectin levels (p = 0.001) and percentage of PDMPs (p < 0.05) in this group was also observed.

Conclusions

HMG-CoA reductase inhibitor therapy in stroke patients with hyperlipidemia may be useful not only due to the lipid-lowering effect but also because of a significant role in reduction of platelet activation and reactivity.     

共刺激分子CD40L在RA患者T细胞亚群中的异常表达

目的　探讨共刺激分子CD4 0L在类风湿关节炎 (RA)患者的T细胞亚群上的表达异常与免疫功能紊乱的关系。方法　用流式细胞仪采用直接免疫荧光法测定 4 6例RA患者和 2 0例健康对照人外周血T细胞表面标志CD3、CD4、CD8的表达情况及CD4 0L在CD4 + T和CD8+ T细胞上的表达。用IMMAGE免疫分析仪 ,速率散射比浊法测定血清中免疫球蛋白的水平。结果　RA患者CD3+ CD4 + 细胞较正常对照组显著增高 (P <0 .0 5 ) ,CD3+ CD8+ 细胞较正常对照组显著降低 (P <0 .0 5 ) ,CD4 + T细胞和CD8+ T细胞上的CD4 0L的表达都较对照组显著增高 (P <0 .0 5 ) ;血清中 3种免疫球蛋白IgG、IgA、IgM的水平均较对照组显著增高 (P <0 .0 5 )。结论　RA患者以CD4 + T细胞活化为主 ,CD4 + T细胞和CD8+ T细胞上高表达的CD4 0L为T细胞活化提供第二信号 ,促使RA患者的细胞免疫功能亢进 ,同时诱导B细胞增生 ,产生大量免疫球蛋白。CD4 0 CD4 0L途径在RA免疫功能紊乱中起了重要作用     

Evidence for the presence of activated CD4 T cells with naive phenotype in the peripheral blood of patients with rheumatoid arthritis.

We have investigated whether T cell activation in rheumatoid arthritis (RA) preferentially engages distinct T cell subpopulations in the peripheral blood (PB) and in the synovial fluid. We found that CD25 expression was enhanced among PB CD4 T cells of RA patients as compared with CD4 cells of patients with reactive arthritis, degenerative joint disease or of healthy controls. Within the CD4 T lymphocytes subset we found that the CD45RO- (naive) cells selectively in RA displayed higher levels of CD25 protein and of interferon-gamma mRNA expression when compared with the respective subset of all other investigated groups. These results show that in the PB of RA, but not in the PB of the other arthropathies or healthy controls, CD45RO-CD4 T lymphocytes exist which display well-defined signs of activation.     

血栓性脑血管疾病患者治疗前后血小板活化膜表面糖蛋白检测及临床意义

目的 :探讨血栓性脑血管疾病患者治疗前后血小板活化标记物CD62 P,GPⅡb/Ⅲa的表达及其临床应用价值。方法 :采用流式细胞仪 (FCM )检测治疗前后血小板活化标记物CD62 P、GPⅡb/Ⅲa的表达。结果 :血栓性脑血管疾病患者治疗前血小板活化标志物CD62 P、GPⅡb/Ⅲa分别为CD62 P5 2 .19± 12 .3 7% ,GPⅡb/Ⅲa 77.98± 14 .2 2 % ,较正常对照组有显著性升高 (P <0 .0 1) ;治疗后CD62 P3 1.16± 17.43 % ,GPⅡb/Ⅲa 40 .71± 11.64 %较治疗前有显著性下降 (P<0 .0 1) ,但仍高于正常对照组 (P <0 .0 1)。结论 :血小板活化标志物CD62 P、GPⅡb/Ⅲa对血栓性脑血管疾病的诊断具有重要价值 ,为临床症状缓解后患者长期药物预防提供理论依据     

Selective increase of activation antigens HLA-DR and CD38 on CD4+ CD45RO+ T lymphocytes during HIV-1 infection.

Infection with HIV results in a progressive depletion of CD4+ T cells and leads to significant in vivo lymphocyte phenotype changes. In this regard, the expression of HLA-DR and CD38 on CD8+ T cells has been shown to increase dramatically with disease progression. We investigated the expression of both activation markers on CD4+ T cells in HIV-1-infected subjects at different clinical stages of infection and compared the in vivo activation of CD4+ T cells with parameters of viral activity and CD8+ T cell activation. Fresh peripheral venous blood was obtained from 54 HIV-infected subjects and from 28 uninfected healthy controls. Three-colour immunophenotyping of the CD4+ T cell subset showed that the proportion of CD4+ T cells expressing HLA-DR (10% in HIV-negative controls) or CD38 (62% in HIV-negative controls) was higher in asymptomatic (P < 0.05 for CD38) and symptomatic (P < 0.001 for HLA-DR and CD38) HIV-infected subjects than in controls, whereas the proportion of CD4+ T cells expressing CD45RO (54% in controls) remained relatively unchanged. Simultaneous expression of HLA-DR and CD38 on CD4+ T cells increased from 2.3% in controls to 11% (P < 0.001) in asymptomatic and 22% (P < 0.001) in symptomatic HIV-infected subjects. This relative increase of CD38 and HLA-DR expression occurred mainly on CD4+ T cells co-expressing CD45RO. Changes in expression of HLA-DR and CD38 on CD4+ T cells correlated with similar changes on CD8+ T lymphocytes, with the presence of HIV antigen in the circulation, and with the disease stage of HIV infection.     

老年原发性肾病综合征患者肾组织和外周血CD62P的表达及意义

目的研究老年原发性肾病综合征(APNS)患者外周血和肾组织CD62P表达水平的变化,并探讨CD62P在APNS病理过程中的作用.方法采用流式细胞术和直接免疫荧光法,对36例APNS患者外周血和肾活检组织CD62P的表达进行研究.结果APNS患者外周血CD62P的表达明显高于正常对照组,有显著性差异(P＜0.01);肾组织CD62P的表达32例(88.89%),表达部位主要在肾小球系膜区和毛细血管袢,与常规肾脏病理检查所观察到的病变部位及其病变程度相一致.正常对照组肾组织中无CD62P表达.结论CD62P在APNS患者外周血和肾组织中表达增强,CD62P可能参与了APNS的病理过程,外周血和肾组织CD62P的变化可反映APNS的病情严重程度,具有重要的临床价值.     

Decreased expression of CD7 occurs in rheumatoid arthritis.

To evaluate the possibility of antigenic modulation in vivo, we studied the expression of the CD7 antigen on the surface of peripheral blood and intrasynovial lymphocytes from patients with rheumatoid arthritis (RA). This disease is noted for features predicting changes in CD7: (1) increased expression related to activation during an immune response through possible contact with 'disease associated antigens' and (2) decreased expression associated with lymphocytes moving through tissue. We found a highly significant decrease of CD7 on RA T cells in vivo (P less than 10(-4] that was not related to disease activity, drug ingestion, or abnormalities in the ability of RA T cells to express or modulate the antigen in vitro. Similar decreased expression was observed on many intrasynovial T cells that were nevertheless activated as measured by expression of activation markers such as Act I (a late lymphocyte activation antigen) and Act II (the transferrin receptor). Decreased expression of CD7 occurs naturally in vivo in RA; this observation may have future significance in better understanding the immunopathogenesis of this disease.